Drug intelligence / Profile preview

68Ga-NOTA-Aca-BBN

Development stage: Phase 1
Lead developer: Peking Union Medical College Hospital
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

68Ga-NOTA-Aca-BBN is a radiopharmaceutical diagnostic imaging agent developed by Peking Union Medical College Hospital for the detection and evaluation of primary gliomas using positron emission tomography/computed tomography (PET/CT). The agent consists of a bombesin (BBN) peptide analog, specifically the 7-14 fragment, conjugated to the chelator NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) via an aminocaproic acid (Aca) linker, and labeled with the positron-emitting isotope Gallium-68. It targets the gastrin-releasing peptide receptor (GRPR), which is frequently overexpressed in various tumors, including gliomas. By binding to GRPR, the tracer allows for non-invasive visualization of tumor extent and receptor density, potentially aiding in the diagnosis and grading of brain tumors.

Other names: 68Ga-labeled NOTA-Aca-BBN(7-14)Gallium-68 NOTA-Aca-BBNGallium68 NOTA-Aca-BBNGallium 68 NOTA-Aca-BBN

Targets

NMBR (Neuromedin B receptor)BRS3 (Bombesin receptor subtype 3)GRPR (Gastrin-releasing peptide receptor)

Beyond the preview

Go deeper on 68Ga-NOTA-Aca-BBN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-NOTA-Aca-BBN.

Explore the full profile